Fused Ring Anthranilate Derivatives for Anti-Fibrotic Therapy

The patent divides the molecular structure of tranilast into distinct functional segments and modifies specific portions. By segmenting the molecule and selectively modifying particular groups (such as changing the anthranilic acid core to fused ring systems), the invention maintains the anti-fibrotic active segments while removing or modifying segments responsible for harmful effects and genetic interactions.

The patent systematically changes molecular parameters including chemical structure, stereochemistry, and physical properties. By altering parameters such as replacing hydrogen atoms with different groups, changing bond configurations, and modifying molecular weight, the invention creates derivatives that maintain therapeutic efficacy while reducing harmful effects and genetic susceptibility issues.

The patent identifies harmful factors in the original tranilast structure (such as specific functional groups causing side effects) and converts them into beneficial features. By modifying these problematic segments into different chemical groups, the invention transforms potential harmful elements into components that enhance safety profile while preserving anti-fibrotic activity.

The patent creates composite molecular structures by combining different chemical moieties in fused ring systems. These composite structures integrate the beneficial anti-fibrotic properties of tranilast with the safety advantages of alternative chemical groups, resulting in molecules that achieve effective fibrosis treatment with reduced side effects.